Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 51-57

  Miyamoto, Yuichir ^a   Nakagawa, Shunsuke ^c   Wada Hiraike, Osamu ^a   Seiki, Takayuki ^a   Tanikawa, Michihiro ^a   Hiraike, Haruko ^a   Sone, Kenbun ^a   Nagasaka, Kazunori ^a   Oda, Katsutoshi ^a   Kawana, Kei ^a   Nakagawa, Keiichi ^b   Fujii, Tomoyuki ^a   Yano, Tetsu ^a   Kozuma, Shiro ^a   Taketani, Yuji ^a  

^a Departments of 1Obstetrics and Gynecology   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

Author keywords

Bortezomib; Cell growth; Cervical cancer; Cisplatin; Combination therapy; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CISPLATIN; DLG PROTEIN; PACLITAXEL; PROTEASOME; PROTEIN P53; SCRIB PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CARBOPLATIN; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED ICR; MICE, SCID; PACLITAXEL; PYRAZINES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84872872660     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2072     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. American Cancer Society: Cancer Facts and Figures 2011. http://www. cancer. org/Cancer/CervicalCancer. 2011.
3. Carter JR, Ding Z and Rose BR: HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 51: 103-108, 2011.
4. Berek JS and Hacker NF (eds): Practical Gynaecologic Oncology. 4th edition. Lippincott Williams & Wilkins, Philadelphia, PA, 2005.
5. Nakagawa S, Watanabe S, Yoshikawa H, Taketani Y, Yoshiike K and Kanda T: Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology 212: 535-542, 1995.
6. Crook T, Tidy JA and Vousden KH: Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67: 547-556, 1991.
7. Huibregtse JM and Beaudenon SL: Mechanism of HPV E6 proteins in cellular transformation. Semin Cancer Biol 7: 317-326, 1996.
8. Massimi P, Gammoh N, Thomas M and Banks L: HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation. Oncogene 23: 8033-8039, 2004.
9. Nakagawa S and Huibregtse JM: Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 20: 8244-8253, 2000.
10. Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789, 2005.
11. Adams J and Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 22: 304-311, 2004.
12. Birle DC and Hedley DW: Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 67: 1735-1743, 2007.
13. Kamer S, Ren Q and Dicker AP: Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341). Arch Gynecol Obstet 279: 41-46, 2009.
14. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S and Roden RB: Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 15: 570-577, 2009.
15. Jiang Y, Wang Y, Su Z, et al: Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. Mol Med Rep 3: 613-619, 2010.
16. Bruning A, Vogel M, Mylonas I, Friese K and Burges A: Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets 11: 799-809, 2011.
17. Frankel A, Man S, Elliott P, Adams J and Kerbel RS: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6: 3719-3728, 2000.
18. Nagasaka K, Nakagawa S, Yano T, et al: Human homolog of Drosophila tumor suppressor Scribble negatively regulates cell-cycle progression from G1 to S phase by localizing at the basolateral membrane in epithelial cells. Cancer Sci 97: 1217-1225, 2006.
19. Morita Y, Wada-Hiraike O, Yano T, et al: Resveratrol promotes expression of SIRT1 and StAR in rat ovarian granulosa cells: an implicative role of SIRT1 in the ovary. Reprod Biol Endocrinol 10: 14, 2012.
20. Wada-Hiraike O, Yano T, Nei T, et al: The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha. Br J Cancer 92: 2286-2291, 2005.
21. Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446, 2010.
22. Kanai R, Wakimoto H, Martuza RL and Rabkin SD: A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 17: 3686-3696, 2011.
23. Fraval HN and Roberts JJ: G1 phase Chinese hamster V79-379A cells are inherently more sensitive to platinum bound to their DNA than mid S phase or asynchronously treated cells. Biochem Pharmacol 28: 1575-1580, 1979.
24. Nawrocki ST, Bruns CJ, Harbison MT, et al: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1: 1243-1253, 2002.
25. Munger K and Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res 89: 213-228, 2002.
26. Adams J: The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29 (Suppl 1): 3-9, 2003.
27. Ling YH, Liebes L, Jiang JD, et al: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9: 1145-1154, 2003.
28. Mortenson MM, Schlieman MG, Virudachalam S and Bold RJ: Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 54: 343-353, 2004.
29. Voortman J, Checinska A, Giaccone G, Rodriguez JA and Kruyt FA: Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther 6: 1046-1053, 2007.
30. Tewari KS and Monk BJ: Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 7: 419-434, 2005.
31. Gregory MA and Hann SR: c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20: 2423-2435, 2000.
32. Jackel M and Kopf-Maier P: Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas. Cancer Chemother Pharmacol 27: 464-471, 1991.
33. Fahy BN, Schlieman MG, Virudachalam S and Bold RJ: Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 113: 88-95, 2003.